EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Personal reflections on the early days of kinase inhibitor probes

Philip Cohen iD

Essays in Biochemistry · 08.05.2026

DOI: 10.1042/ebc20260003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Essays in Biochemistry, online erschienen am 08.05.2026. Verfasst von Philip Cohen. Beteiligte Einrichtung: University of Dundee, Sir James Black Centre, School of Life Sciences, Dow Street, Dundee DD1 5EH, U.K. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI | Medical Research Council (MRC), Diabetes UK (DIABETES UK LIMITED), Royal Society (The Royal Society).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first protein kinases and their role in cell regulation were identified in the mid-1950s, but it was not until the 1980s that the first inhibitors of these enzymes were developed. More specific inhibitors that suppressed kinase activity at low nanomolar concentrations were described in the mid-1990s and their potential to treat cancers caused by kinase mutation became clear during the late 1990s. Over 100 protein and lipid kinase inhibitors have now been approved for clinical use during the 21st century with combined annual sales of over US$ 65 billion in 2024. They have not only transformed the clinical care of multiple malignancies but have also been exploited widely to identify physiological substrates and cellular functions of these enzymes. Here, I present some personal reflections on the early days of kinases and their inhibitors, give a few examples of how they were first exploited to dissect signal transduction pathways and explain how the first panels of protein kinases came to be established to facilitate the development of more specific kinase inhibitors.

Schlagwörter

Stichwörter der Autor:innen

cancerdrug discovery and designinositide signallingprotein-serine-threonine kinases

Autor:innen und Institutionen

  • University of Dundee, Sir James Black Centre, School of Life Sciences, Dow Street, Dundee DD1 5EH, U.K.

ORCID-Profile: Philip Cohen

Förderung

  • UKRI | Medical Research Council (MRC)
  • Diabetes UK (DIABETES UK LIMITED)
  • Royal Society (The Royal Society)

Zitieren

APA

Cohen, P. (2026). Personal reflections on the early days of kinase inhibitor probes. Essays in Biochemistry. https://doi.org/10.1042/ebc20260003

Vancouver

Cohen P. Personal reflections on the early days of kinase inhibitor probes. Essays in Biochemistry. 2026. doi:10.1042/ebc20260003

BibTeX
@article{Cohen2026,
  author = {Cohen, Philip},
  title = {Personal reflections on the early days of kinase inhibitor probes},
  journal = {Essays in Biochemistry},
  year = {2026},
  doi = {10.1042/ebc20260003}
}
Kostenlos starten →